LEAF-4L6715
Small molecule
LEAF-4L6715 is one of 33 small molecule programs targeting Acute Respiratory Distress Syndrome. It is currently in development.
1
Indications
2
Total Trials
1
Active Trials
32
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
146 competitors in Acute Respiratory Distress Syndrome
#DrugCompanyPhaseTrials
1Medrol
PfizerPhase 3
Plaquenil
Alnylam PharmaceuticalsPhase 3
Zulresso
BiogenPhase 3
Activase
RochePhase 3
Ultomiris
AstraZenecaPhase 3
Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Inomax
MMallinckrodt
Phase 3
Vafseo
AAkebia Therapeutics
Phase 3
Brevibloc
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Nizoral
WWim Janssens
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for LEAF-4L6715. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Company
- LLEAF4Life, Inc.